International Journal of Biotech Trends and Technology
ISSN: 2249 – 0183 /doi:10.14445/22490183/IJBTT-V11I3P602

Volume 11 Issue 3, 8-17, July-Sep 2021

Computer-aided and Herbal Informatics based Drug Designing for Potential Lung Cancer Therapeutics

Debanjoy Paul [#1], Preeti Pannu[2], Madhavi Sinha[2], Vaishali Bisht[2*]

[1]*Bannari Amman Institute of Technology, Sathyamangalam, Tamilnadu, India 638 401.*
[2]*Rapture Biotech International (P) Ltd, Noida Sector 10, Uttar Pradesh, India*

Received Date: 02 June 2021
Revised Date: 10 July 2021
Accepted Date: 20 July 2021

ABSTRACT
Lung was very rare at the beginning of the last century, but later according to a cancer statistic report, it becomes the most common cancer worldwide since 1985. But there are still multiple risk factors, including environmental, hormonal, genetic, and viral, that have been implicated in the pathogenesis of lung cancer in never-smokers; no related factor has been there that can explain the high incidence of lung cancer in never-smokers. Drug design describes the search of novel compounds with biological activity on a systematic basis. The drug design process has focused on the molecular determinants of the interactions between the drug and molecular target. It is cost-efficient, time-saving, and the process is automatic. We can also know the drug-receptor interaction pattern. Through searching huge libraries of phytochemicals compounds, it can give high hit rates compounds comparison to other high throughput screening, and there is a little chance of failures in the final phases.

KEYWORDS: *Cancer, CADD, Therapeutics, Phytochemicals, and Lung cancer*

I. INTRODUCTION

Recently, worldwide, there are 2.1 million new cases of lung cancer, with 1.8 million deaths predicated, creating lung cancer the leading reason behind cancer-related mortality. [1] Among males, lung cancer is the main cause of death in countries like Eastern Europe, Western Asia, Northern Africa, and specific countries in Eastern Asia, India (China), and South-Eastern Asia (like the Philippines and Myanmar). Among females, the highest rates of lung cancer are seen in North America, French, China, Denmark, and Hungary top of the list, as shown in (fig.1). Active smoking prevention and cessation programs are introduced, the proportion of lung cancer among non-smokers is expected to increase. Globally, lung cancer reveals a pronounced gender bias in never smokers, occurring more commonly in females. A high proportion of Asian women diagnosed with lung cancer are never smokers in particular.



Fig 1:- Global Lung Cancer Incidence. Global age-standardized incidence rates for lung Cancer are 20 countries with the highest rate internationally. Reproduced from GLOBOCAN 18

Although smoking-related cancer agents act on both proximal and distal airlines inducing all

of the major kinds of respiratory organ cancer, cancers arising in never-smokers target the distal airlines and favor adenocarcinoma histology. [2] Smokeless tobacco contains weak carcinogens, and there is little chance of causing lung cancer in never smokers. [3] Distinctly different mutation patterns and frequencies between lung cancers in non-smokers are shown in molecular studies, especially of the RBM10, KRAS, and epidermal growth factor receptor (EGFR) [4]. [5] Significant gender, clinical-pathological and molecular variations in lung cancers that occur in non-smokers strongly suggest a disease that is different from the more common types of lung cancer associated with tobacco [6]. Never-smokers having lung cancer is more advanced disease, usually at a younger age, again indicating a biologically distinct disease from lung cancer due to tobacco.[7] About 63000 new cases of lung cancer are registered in India each year [8], and this condition is mostly seen only as a smoker's disease. A large number of lung cancer patients, however, may not have a history of smoking. A report has been taken from different cities like Pune, Delhi, Chennai, and Bangalore, as shown in (fig 2) where Lung cancer showed a significant increase in 4 PBCRs among females. [9]



Fig 2:- Comparison of lung cancer of top Lung cancer registries cities in India taken from National Cancer Registry Programme, India.

II. IN-SILICO DRUG DESIGN AND COMPUTER-BASED DRUG DESIGN

Drug discovery is mostly portrayed as a linear, consecutive process that starts with the target and leads the discovery, followed by lead optimization and pre-clinical in vitro and in vivo studies to determine if such compounds satisfy a number of present criteria for initiating clinical development. For the pharmaceutical industry, the number of years to bring a drug from discovery to market is approximately 12-14 years and costing up to $1.2 - $1.4 billion dollars. [10]

In-silico is a term used to mean "performed on the computer or via computer simulation" *In-silico* method can help in identifying the drug target in some simple steps shown in (fig 3). They can be used to identify the target structures for specific or different binding sites, generate candidate molecules, check their drug similarity, dock this molecule with the target, rank them according to their binding affinities, further modify the molecules to enhance binding features. Computational models are developed for various diseases or receptors where one can check the binding affinity, efficacy, and ADME (Absorption, Distribution, Metabolism, and Excretion) parameters. In these, one have to just prepare various molecules in virtual form and by in-silico software, and there are various parameters that can be checked, and screening becomes easy, fast, and less costly compared to the traditional method where one has to synthesize all the molecules (and it is in thousands range) in the wet lab and screen them one by one which is time-consuming [11]. 2 types of methods to permeate all aspects of drug discovery today a forms the core of (a) structure-based drug design & (b) ligand-based drug design.



Fig 3:- Flow Diagram: *In silico* drug discovery process briefing the crucial steps of computer-aided drug designing.

(a) Structure-based drug design (SBDD): Structure-based drug design is the technique where target protein is known for all the tested compounds. SBDD runs multiple cycles before its optimized lead gets ready for clinical trials. The first cycle, i.e., isolation, purification, and determine the structure of the target protein with any of the three methods like NMR, X-ray crystallography, or homology modeling. After that, virtual screening is done on the selected region (active site) of the protein. These compounds scored and position based on the hydrophobic, electrostatic interaction of these molecules is calculated after docking is over to design a new drug molecule, which shows strong interaction with the target protein [12]. In the second phase of cycle determination of the protein in complex with the optimized lead done on the first cycle, where one with the minimum micromolar inhibition in-vitro and it shows the site where the compound can be optimized for further increment in the potency. After several cycles of leads, further optimization of the compound shows a marked increment in the target species and binding affinity [13].

(b) Ligand-based drug design (LBDD):(b) Ligand-based drug design (LBDD): The ligand-based drug design approach involves the analysis of ligands known to interact with a target. These methods use a collection of reference structures collected from compounds known to interact with the target of interest and analysis their 2d or 3D structure. In some cases, usually during which data concerning the 3D structure of a target macromolecule aren't accessible, drug design will instead be based on the method using the known ligands of a target macromolecule because of the starting point. This method is known as "ligand-based drug design.[14]

III. ADVANTAGE OF IN-SILICO AND COMPUTER-BASED DRUG DESIGN

These days discovery of new drugs is a very complex process that takes lots of time and resources. So, nowadays, computer-aided drug design has been introduced and is used all over the world for drug development. Various approaches to computer-aided drug design have promising techniques for the needs. In between all these, there are two types of techniques, i.e., structure-based and ligand-based drug design which is a very efficient technique. It can reduce synthetic and biological efforts.[15]. Through in-silico filters, it gives a promising drug candidate by eliminating all the compounds with undesirable properties [16].

IV. TARGET OF LUNG CANCER

A. K-RAS

RAS is one of every of the foremost necessary molecules within the EGFR downstream sign pathway. 3 human RAS factors are identified: HRAS, KRAS, and NRAS. They're tiny GTP-GDP–binding macromolecules that act as purposeful switches by coupling protein receptors to animate thing signaling pathways. RAS will activate the enzyme RAF, the mitogen-activated living thing signal-regulated kinases (ERK)1 and ERK2, PI3K, and plenty of alternative proteins to push cell proliferation. As a result of activation of the EGFR ends up inactivation of the intracellular effector KRAS, it absolutely was hypothesized that mutations in the KRAS committal to writing gene could lead to a constitutively activated KRAS protein that is freelance from upstream signals, that later on may have an effect on clinical response to EGFR inhibitors. Mutations within the KRAS factor occur in more or less thirty-five to 40% of carcinoma, are single ester purpose mutations principally in codons twelve and thirteen of desoxyribonucleic acid 2, and are early events throughout the event of colon cancer carcinogenesis. The mutations of K-RAS are identical throughout all stages, and an awfully high concordance has been according to paired primary cancers and pathological process samples.

there's no complete agreement on the prognostic role of KRAS mutations.[17] The central role K-, H- and N-Ras play in control diverse cellular pathways necessary for cell growth, differentiation, and survival is well established. Dysregulation of Ras proteins by activating mutations, overexpression of upstream activation is common in human tumors. Of the Ras proteins, K-ras is that the most often mutated and is thus a gorgeous target for cancer therapy. The complexness of the K-ras sign presents several opportunities for therapeutic targeting. A variety of various approaches aimed toward abrogating K-ras activity are explored in clinical trials.[18]

B. RBM10

RNA binding proteins (RBPs) are a big and wide elegance of proteins that adjust all elements of RNA metabolism. RBPs are, therefore, involved in regulating the nature, amount, and functionality of gene expression products. In 1995 it was the first cloned from human bone marrow.[19] In 1996, RBM10 (as S1-1) cDNA became cloned from rat liver in a focused try to signify a wonderful subset of nuclear hnRNA-related proteins.[20] The full-length RBM10 transcript is about 3.5 kb long, divided into 24 exons, and translated right into a protein of 930 amino acids.RBM10 is expressed in maximum, if now no longer all, cell types (Gene Cards data), even though one RBM10 allele is silenced in somatic girl cells through X chromosome inactivation.[21] A requirement for RBM10 expression for the duration of improvement is evidenced through research displaying that loss-of-characteristic mutations are the motive of TARP syndrome, a strange developmental syndrome commonly ensuing inside the affected kid's death before or soon after birth.[22][23] RBM10 mutations also are found in some of most cancers types.[24] The affiliation of RBM10 mutation with sickness states isn't always sudden as altered RBP expression and/or characteristic is related to an extensive spectrum of diseases, maximum being of neurological, muscular, sensory, or neoplastic origin.[25] The medical importance of rbm10 and its Functional and regulation is highlighted in conditions where RBM10 expression is disrupted. For instance, RBM10 mutations are the purpose of TARP syndrome.[26] This situation is characterized by many developmental abnormalities, mainly craniofacial deformities inclusive of cleft palate, glossoptosis (tongue displacement), and micrognathia (undersized jaw), which could purpose issues consuming and breathing. RBM10 mutations, consisting of chronic lung disease, visual impairment, large highbrow disability, and an incapability to eat or sit independently. [27]

C. VEGFR-2

There is much proof that VEGFR-2 (KDR) is the fundamental mediator of VEGFA-pushed responses in endothelial cells, and it's far taken into consideration to be a critical sign transducer in each physiologic and pathologic angiogenesis. In addition, VEGFR-2 binds proteolytically processed VEGFC and VEGF-D. VEGFR-2 is expressed in maximum if now no longer all grownup vascular endothelial cells, in addition to in circulating endothelial progenitor cells, pancreatic duct cells, retinal progenitor cells, megakaryocytes, and hematopoietic cells. VEGFR-2, frequently in aggregate with VEGFR-3, is notably upregulated withinside the tumor vascular endothelium in maximum not unusual place human strong tumor types.[28] Tumor cells may be specific VEGFR-2, despite the fact that epithelial and mesenchymal tumor cells normally specific VEGFR-1 instead of VEGFR-2. Nevertheless, extended-expression of VEGFR-2 on tumor cells has been stated for cancer and hematological malignancies. It has been proven that VEGFR-2-mediated signaling brought about the survival of most cancers cells below continual hypoxic situations and may make a contribution to a greater competitive phenotype. Growing proof helps a critical hyperlink among continual infection and tumor development. Induction of VEGFR-2 expression in tumor cells, and additionally in the intestinal epithelium at some point of colitis, is mediated with the aid of using the pro-inflammatory cytokine interleukin 6, which's a robust promoter of tumor boom in experimental colitis-related colon most cancers. VEGF-2 has been defined and might have critical organic roles. VEGF-2 binds VEGFC and hence prevents activation of been lately proven that downregulation of sVEGFR-2 in superior metastatic neuroblastoma can also additionally sell lymphogenic unfold of metastases. [29]

BRAF

BRAF change in NSCLC is presently perceived as an uncommon type of cellular breakdown in the lungs. The information has started to arise the utilization of BRAF/MEK inhibitors with the end goal that targets BRAFV600E mutations in the mitogen-enacted protein kinase (MAPK) pathway.[30] Different stage 2 contemplating have been performed evaluating the viability of single specialist BRAF hindrance and blend BRAF/MEK restraint in pretreatment and untreated understanding populaces. Continuously by and large reaction rate (OR BRAF is essential for the mitogen-actuated protein kinase (MAPK) pathway, which assumes a significant part in charge of the cell development and guideline. [31] In solid tissue, the BRAF kinase is deactivated through negative input once the sign has continued on to the following point in the course. [32] BRAF transformations happening in the MAPK pathway brings about proceeding with the actuation of downstream cell flagging. BRAF changes act thusly act as oncogenic drivers, which can show unchecked cell development and expansion, and movement-free endurance (PFS) are refined with the expansion of a MEK inhibitor.[33] RAF elective answerable for this cycle is a BRAF point transformation, V600E. This point in the cell pathway has shown up as a useful restorative objective for drug treatment with BRAF inhibitors. Obstruction consistently creates with getting present opposition presentation on BRAF/MEK restraint remains the most requesting part of treating patients with these medications.[34] Actuation and cross visit between equal pathways are considered a typical component that tumor cells use to beat the nearby press by the BRAF/MEK inhibitors. The

PI3K/AKT/mTOR pathway is freely connected to the MAPK pathway.[35] In the encompassing of BRAF/MEK, restraint cell flagging is up to change over the long run through this pathway grant continuous tumor movement through this substitute pathway. The advancement of sidestep pathways going about as redirection of cell motioning along MEK 1/2 kinases.BRAF changes are uncommon in non-little cell cellular breakdown in the lungs (NSCLC), which happen in 1–5% of cases.[36] BRAF transformations are most normally distinguished in lung adenocarcinoma. BRAFV600E is persistently announced as the most well-known variation perceive, present in over half of cases with a BRAF transformation. The public far-reaching malignancy organization (NCCN) and European culture of clinical oncology (ESMO) rules now initial testing for BRAF changes in NSCLC, specifically BRAFV600E.[37] This guidance endorses the utilization of BRAF/MEK inhibitors in first or progressive lines of treatment for those that bear a V600E change.[38]

EGFR

Epidermal improvement factor receptor (EGFR) is a transembrane protein with cytoplasmic kinase activity that transducing huge advancement factor motioning from the extracellular setting to the cell.[39] Verified that over 60% of non-little cell lung carcinomas (NSCLCs) show EGFR, EGFR has become a huge reestablishing objective for the treatment of these tumors. Inhibitors that emphasize the kinase space of EGFR have been creating and are clinically powerful. [40] Even more, altogether, such tyrosine kinase inhibitors (TKIs) are essentially successful in patients whose tumors harbor turn-on changes in the tyrosine kinase space of the EGFR quality.[41] Most recent starters have been showing that for forefront NSCLC patients with EGFR crack tumors, starting treatment with a TKI in lieu of chemotherapy may be the best choice of treatment. Hence, change testing is important to perceive these patients, given that grouping subject to clinicopathologic credits is inadequate.[42] We assessment the work of EGFR changes in the assurance and control of NSCLC. Cell breakdown in the lungs is the second most ordinary unsafe tumor and the central wellspring of dangerous development death.[43] Epidermal advancement factor receptor (EGFR)- crack non-little cell breakdown in the lungs (NSCLC) is an overall described subtype of cell breakdown in the lungs contain circuitous 15-40% of non-squamous tumors. The improvement of first-and second-age EGFR tyrosine kinase inhibitors (TKIs) has been a striking stamp ahead in the treatment of patients with EGFR-crack tumors, or more the latest couple of years has been the treatment of game plan initially thought of patients with turn on changes in EGFR, with some distinction insufficiency and harmfulness chart. Up to half of the patients sustain with first-and second-age TKIs develop an EGFR exon 20 T790M change at the hour of progress.[44]

V. PHYTOCHEMICAL

For a long time, herbal medicine has been used as anti-carcinogens. They contain exhibit anti-inflammatory activities and abundant anti-most cancers compounds that exert direct cytotoxicity outcomes and oblique regulation in the tumor microenvironment and cancer immunity, in addition to enhance chemotherapy[45]. For example, PNAS reported that epigallocatechin gallate (EGCG) focused on Laminin receptor (Lam 67R) shows promising efficacy in treating prostate cancer. Numerous herbal products originated from natural medicine exhibit anti-most cancers activities, including anti-proliferative, pro-apoptotic, anti-metastatic, anti-angiogenic effects, in addition to modify autophagy, reverse multidrug resistance, stability immunity, and enhance chemotherapy in vitro and in vivo. To provide new insights into the vital route ahead, A systemically reviewed is taken on the key compounds with anti-cancer effects derived from natural medicine (curcumin, resveratrol, sulforaphane)

A. CURCUMIN

Curcumin is a polyphenol compound extracted specifically from the rhizomes of *Curcuma longa*, *Curcuma zedoaria*, and *Acoruscalamus* L. with many organic activities; however, it has poor water solubility and stability[46]. Clinical proof and extensive research showed that curcumin has numerous pharmacology effects, which include anti-cancer, anti-inflammatory, and anti-oxidative activities. Curcumin and its analogs are shown to be rising as effective agents for the treatment of several malignant diseases like cancer.[47]

Curcumin also inhibits cell growth, induces molecular cycle arrest, and apoptosis in esophageal squamous cell carcinoma EC1, EC9706, KYSE450, TE13 cells thru STAT3 activation. It additionally induces oxidative stress, which disrupts the mitochondrial membrane ability and causes the release of cytochrome c, therefore inducing apoptosis. Besides, curcumin is proven to result in autophagy[48]. It induces autophagy via 5′AMP-activated protein kinase (AMPK) activation, leading to Akt degradation, as a result inhibiting cell proliferation and migration in human breast cancer MDA-MB-231 cells, at the same time, it inhibits cell increase partly thru autophagy induction in human hepatocellular carcinoma HepG2 cells. Moreover, curcumin can ameliorate Warburg's impact in human non-small cell lung most cancers (NSCLC) H1299, breast most cancers MCF-7, cervical most cancers HeLa and prostate cancer PC-three cells thru pyruvate kinase M2 down-regulation, a key regulator of Warburg effect. In addition, tumor metastasis has constantly been a frustrating problem for anti-cancer therapy, and curcumin additionally exhibits anti-metastasis effects. Curcumin also can exert immunomodulatory effects against cancer cells. Theracurmin, a highly bioavailable form of curcumin, reduces the pro-inflammatory cytokine secretion from activated T cells and increases cytotoxicity caused by T cells in human esophageal adenocarcinoma OE33 and OE19 cells, so it will increase the sensitivity of the cells to T cell-caused cytotoxicity[49].

B. RESVERATROL

Resveratrol is growing in prominence because it showed cancer-preventive and anti-cancer properties [50]. A non-

flavonoid polyphenol, resveratrol is a phytoalexin that naturally takes place in many species of plants, and it includes peanuts, grapes, pines, and berries, and assists with inside the reaction towards pathogen infections. Interestingly, Chinese and Japanese traditional medicinal drugs additionally contain it, in the shape of extracts such as from Polygonum cuspidatum, which can be used to address inflammation, headaches, cancers, and amenorrhea. In the preclinical model, when the BP-induced mouse lung carcinogenesis model, resveratrol treatment lowered the BP diol epoxide adduct, and it improved the ultra histoarchitecture[51], and the size of the tumor reduced the tumor nodules by increasing pulmonary caspase-3 and -9 activity [52]. Another study discovered that resveratrol has no effect on the development of Lewis lung carcinoma implanted in mice. However, it confirmed an obvious anti-metastatic effect, lowering each weight and number of lung metastases[53].

C. SULFORAPHANE

Sulforaphane is an isothiocyanate compound usually observed in cruciferous vegetables, like broccoli, brussels sprouts, kale, and cabbages. Similar to curcumin and resveratrol, sulforaphane has received lots of attention in anticancer research. And it possesses various anticancer mechanisms in cancer cells [54]. Sulforaphane, by its virtue of inhibiting, has been proven to inhibit lung inflammation via induction and the enzyme showed two-phase expression. The inflammatory effects of particulate pollutants, like tobacco smoke, get blocked by sulforaphane via upregulation of the phase two enzymes in the lung epithelial cells. Sulforaphane inhibits NF-κB activation of binding to the cysteine residues of NF-κB. Furthermore, the activity of redox modulators, including GSH, Ref-1, and thioredoxin, is pivotal for NF-κB function and is said to be intercepted on interaction with the sulforaphane. [55].

EPIGALLOCATECHIN

Epigallocatechin-3-gallate (EGCG), a green tea–decided polyphenol, display antitumor occupation. An EGCG nanoemulsion (Nano-EGCG) was set up to improve the steadfastness and reduction of the side effects of EGCG for treatment of human cell breakdown in the lungs cells, and the antitumor result was deliberate.. [56] The possible nuclear framework fundamental it's antitumor effects on refined human cell breakdown in the lungs cells was moreover explain. The antitumor effects of EGCG and nano-EGCG were controlled using methyl thiazolyl diphenyl-tetrazolium bromide (MTT), area game plan, development, and occupation test.[57] In the figure, changes in the AMP-started protein kinase (AMPK) hailing pathway were researched using Western smear assessments. AMPK inhibitors were used to assess the pieces of the AMPK hailing pathway remember for the sub-nuclear instrument of the Nano-EGCG.[58] Our results give the possibility that both EGCG and nano-EGCG controlled the advancement of H1299 cell breakdown in the lungs cells, with half-maximal discretion combinations of 36.03 and 4.71 μM, independently. Additionally, Nano-EGCG viably smothered cell breakdown in the lungs cell settlement advancement, migration, and occupation in a segment subordinate way. [59] Nano-EGCG ruins the cell breakdown in the lungs cell get through structure metalloproteinase (MMP)- 2-and MMP without 9 parts. Additionally, the surge of various key regulatory proteins in the AMPK hailing pathway was coordinated by Nano-EGCG.[60] Nano-EGCG curbs the cell breakdown in the lungs cell duplication, state improvement, development, and catch through the vitalizing of AMPK hailing pathways. This hardback instrument of Nano-EGCG reason its application in cell breakdown in the lungs contravention and treatment. [61]

FISTEIN

Fisetin (3, 3', 4', 7-tetrahydroxyflavone) is a natural polyphenolic flavonoid compound found in numerous foods grown from the ground. It shows an assortment of pharmacological exercises, including anticancer and against tumor impacts. [62] Epithelial to mesenchymal progress (EMT) licenses the tumor cells to gets expanded relocating and meddling properties intervening their spreading to inaccessible destinations, the recommended metastasis.[63] With the metastatic cellular breakdown in the lungs asserting most of the cellular breakdown in the lungs related passing's, specialists focusing on the pathways fundamental metastasis are translationally encouraging.[64] In the current examination, we have investigated the counter metastatic impacts of fisetin in non-little cell lung carcinoma (NSCLC) cells A549 and H1299 with accentuation on EMT. The outcomes proposed a huge restraint in relocation and intrusion of NSCLC cells under non-cytotoxic fixations.[65] Moreover, a lessening of the EMT was seen in both the cell lines with up-regulation in the statement of epithelial marker E-cadherin in A549 cells and ZO-1 in H1299 cells with associative down-regulation of the mesenchymal markers vimentin just as N-cadherin alongside intrusion marker MMP-2.[66] Thus, the downregulation of the outflow of NSCLC foundational microorganism signature markers CD44 and CD133 was likewise noticed.[67] Fisetin diminished the declaration of different flagging proteins (β-catenin, NF-κB, EGFR, STAT-3) acting upstream to EMT and is known to be associated with acceptance and upkeep of mesenchymal aggregate, which may clarify the noticed impacts. Additionally, fisetin diminished the capacity of H1299 cells to shape settlements on delicate agar and potentiated the cytotoxic impacts of tyrosine kinase inhibitor (TKI), erlotinib. [68] Generally speaking, our investigation reason the capacity of fisetin to convey as a likely restorative specialist on its ability to lessen the EMT program and restrain movement, catch and undifferentiated organism aggregate of cellular breakdown in the lungs cells. [69]

VEMURAFENIB

BRAF transformations happen in 1%-5% of patients with non-little cell cellular breakdown in the lungs (NSCLC) are helpful focuses for these tumors, yet the impact of the change on clinical occupation is questionable.[70] The French National Cancer Institute (INCA) dispatched the vemurafenib test to assess the impact and welfare of

vemurafenib in tumors with different BRAF mutations. The biochemical compassion of vemurafenib for changed BRAF expresses the incredible obstacle of ERK phosphorylation and of cell expansion totally in BRAF-freak cell lines.[71] In creature model trials, it signified that vemurafenib accomplish tumor retrogression in cells that nurture the BRAF V600E change. The clinical preliminaries with vemurafenib in ineradicable advancement melanoma in stage I, II, and III for patients nurture BRAF V600E transformations signify all unpredicted high fair-minded reaction rates range somewhere in the range of 50 and 80%. [72] Middle turn of events - free period was extended from two months with dacarbazine (otherwise called DTIC) to seven months with vemurafenib, and middle by and large period was separated period from 9 to 14 months. [73] A significant issue that buildup is the improvement of protection from vemurafenib treatment after certain months in most patients, and numerous obstruction procedures as of now have been depicted. Under vemurafenib treatment, about 25% of patients created cutaneous squamous cell carcinomas of the keratoacanthoma (KA) type with low meddling potential and without occasion of metastasis. The generally bearable of the medication was very acceptable, and various patients withstand treatment for long occasions. As other strong tumors like papillary thyroid disease, colorectal malignancy, non-little cell cellular breakdown in the lungs, and ovarian malignancy similarly harbor BRAF change, vemurafenib is additionally tried in these bodies. In the future, mixes of vemurafenib with other kinase inhibitors and with immunotherapies will improve its helpful forthcoming. [74]

Ligand	**Structure**
Curcumin	
Resveratrol	
Sulforaphane	
Epigallocatechin	

Vemurafenib	
Fistein	

Fig 3: - 3D structures of Ligands Curcumin, Resveratrol, and sulforaphane, Epigallocatechin, Fistein, Vemurafenib by Pymol.

VI. CONCLUSION AND FUTURE PROPECTS.

The goal of this review is to provide an overview of current computational drug design and its use in integrated rational drug development to aid in the advancement of drug discovery research in the creation of new lung cancer treatments derived from phytochemical sources. Natural products, in general, have been a major source of chemicals for the treatment of a variety of cancers, and they provide an exciting opportunity to test not only new chemical classes of anticancer drugs but also unique and possibly relevant mechanisms of action. Drug design is the process of coming up with novel treatments based on a biological target's information. Natural products that are capable of altering protein functions in pathogenesis-related pathways can be identified using CADD approaches, making this one of the most promising areas of drug development. There are two types of CADD approaches in this regard: structure-based drug design (SBDD) and ligand-based drug design (LBDD).

Fortunately, with the introduction of new ideas and the development of computational tools and procedures, this situation has lately changed. To improve the efficiency of the drug development process, many new technologies and approaches have been developed. Many drug development initiatives now use computational approaches as a critical component. Techniques like ligand- or structure-based virtual screening are frequently employed in numerous discovery endeavors, from hit detection to lead optimization. This is especially true when it comes to developing possible anticancer medications and therapeutic candidates, where computational approaches have had a significant impact throughout time and have yielded valuable insights into the subject of cancer. Because of its applicability in many stages of drug discovery and development due to multiple sophisticated features, computer-aided drug design (CADD), also known as in silico screening, has become a powerful tool in recent years. The CADD technique will be used in this study to find new lead structures from phytochemical sources that could be used as lung cancer treatment candidates.

CONFLICT OF INTEREST: The authors declare no conflict of interest

VII. REFERENCES

[1] Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008 Int J Cancer (2010) 127:2893-917.

[2] Ganesh B, Sushama S, Monika S, Suvarna P. A Case-control Study of Risk Factors for Lung Cancer in Mumbai, India. Asian Pac J Cancer Prev (2011) 12:357-62.

[3] Toh CK, Gao F, Lim WT, Leong SS, Fong KW, Yap SP, et al. Never-Smokers With Lung Cancer: Epidemiologic Evidence of a Distinct Disease Entity. J ClinOncol (2006) 24:2245-51.

[4] Gajalakshmi V, Hung RJ, Mathew A, Varghese C, Brennan P, Boffetta P. Tobacco smoking and chewing, alcohol drinking and lung cancer risk among men in southern India. Int J Cancer (2003) 107:441-7.

[5] Gealy R, Zhang L, Siegfried JM, Luketich JD, Keohavong P. Comparison of mutations in the p53 and K-ras genes in lung carcinomas from smoking and nonsmoking women. Cancer Epidemiol Biomarkers Prev (1999) 8:297-302.

[6] Hainaut P, Pfeifer GP. Patterns of p53 G-->T transversions in lung cancers reflect the primary mutagenic signature of DNA damage by tobacco smoke. Carcinogenesis 200; 22:367-74.

[7] Durré T, Morfoisse F, Erpicum C, Ebroin M, Blacher S, García-Caballero M, Deroanne C, Louis T, Balsat C, Van de Velde M, Kaijalainen S, Kridelka F, Engelholm L, Struman I, Alitalo K, Behrendt N, Paupert J, Noel A. uPARAP/Endo180 receptor is a gatekeeper of VEGFR-2/VEGFR-3 heterodimerization during pathological lymphangiogenesis. Nat Commun., 5;9(1) (2018) 5178.

[8] Rapisarda A, Melillo G. Role of the VEGF/VEGFR axis in cancer biology and therapy. Adv Cancer Res., 114 **(**2012) 237-67.

[9] Durré T, Morfoisse F, Erpicum C, Ebroin M, Blacher S, García-Caballero M, Deroanne C, Louis T, Balsat C, Van de Velde M, Kaijalainen S, Kridelka F, Engelholm L, Struman I, Alitalo K, Behrendt N, Paupert J, Noel A. uPARAP/Endo180 receptor is a

gatekeeper of VEGFR-2/VEGFR-3 heterodimerization during pathological lymphangiogenesis. Nat Commun., 5, 9(1) (2018) 5178.

[10] Manuela S Murgueitio , Marcel Bermudez , JérémieMortier , Gerhard Wolber. In silico virtual screening approaches for anti-viral drug discovery 9 (2012) 219-2

[11] Imam SS, Gilani SJ. Computer-Aided Drug Design: A Novel Loom To Drug Discovery. Org. Med. Chem., 1(4) (2017) 1-6.

[12] Anderson AC. The process of structure-based drug design. Chemistry & biology. , 10(9) (2003) 787-97.

[13] Prashant Mathur, DNB, PhD[1]; Krishnan Sathishkumar, MSc[1]; MeeshaChaturvedi, MBBS[1]; Priyanka Das, B-Level[1]; KondalliLakshminarayanaSudarshan, MSc[1]; Stephen Santhappan, MSc, MPhil[1]; VinodhNallasamy, MSc, MPhil[1]; Anish John, BE[1]; Sandeep Narasimhan, MSc[1]; and Francis SelvarajRoselind, MSc[1]; JCO GLOBAL Oncology no. 6(2020) 1063-1075.

[14] Chayan Acharya, Andrew Coop, James E. Polli, and Alexander D. MacKerell, "Recent Advances in Ligand-Based Drug Design: Relevance and Utility of the Conformationally Sampled Pharmacophore Approach", Current Computer-Aided Drug Design 7(1) (2011)

[15] FZhang S. Computer-aided drug discovery and development. In Drug Design and Discovery. , (2011) 716:23-38.

[16] Kapetanovic IM. Computer-aided drug discovery and development (CADD): in silicon-chemical-biological approach. Chemical-biological interactions. , 71(2) (2008) 165-76

[17] Duursma AM, Agami R. Ras interference as cancer therapy. Semin Cancer Biol., (2003) 267-73. PMID: 14563121.

[18] Friday BB, Adjei AA. K-ras as a target for cancer therapy. Biochim Biophys Acta., (2005) 1756:127-44. PMID: 16139957.

[19] Imam SS, Gilani SJ. Computer-Aided Drug Design: A Novel Loom To Drug Discovery. Org. Med. Chem., 1(4) (2017) 1-6.

[20] Nagase T, Seki N, Tanaka A, Ishikawa K, Nomura N. Prediction of the coding sequences of unidentified human genes. IV. The coding sequences of 40 new genes (KIAA0121-KIAA0160) were deduced by analysis of cDNA clones from human cell line KG-1. DNA Res. (1995) 2:167-210.

[21] Inoue A, Takahashi KP, Kimura M, Watanabe T, Morisawa S. Molecular cloning of an RNA binding protein, S1-1. Nucleic Acids Res., (1996) 24:2990–2997.

[22] Johnston JJ, Teer JK, Cherukuri PF, et al. Massively parallel sequencing of exons on the X chromosome identifies RBM10 as the gene that causes a syndromic form of cleft palate. Am J Hum Genet., (2010) 86:743–748.

[23] Gorlin RJ, Cervenka J, Anderson RC, Sauk JJ, Bevis WD. Robin's syndrome. A probably X-linked recessive subvariety exhibiting persistence of left superior vena cava and atrial septal defect. Am J Dis Child., (1970) 119:176–178.

[24] Sebestyen E, Singh B, Minana B, et al. Large-scale analysis of genome and transcriptome alterations in multiple tumors unveils novel cancer-relevant splicing networks. Genome Res. , (2016) 26:732–744.

[25] Lukong KE, Chang KW, Khandjian EW, Richard S. RNA-binding proteins in human genetic disease. Trends Genet. (2008) 24:416–425.

[26] Gripp KW, Hopkins E, Johnston JJ, Krause C, Dobyns WB, Biesecker LG. Long-term survival in TARP syndrome and confirmation of RBM10 as the disease-causing gene. Am J Med Genet A 155A? (10) (2011) 2516–2520.

[27] Powis Z, Hart A, Cherny S, et al. Clinical diagnostic exome evaluation for an infant with a lethal disorder: genetic diagnosis of TARP syndrome and expansion of the phenotype in a patient with a newly reported RBM10 alteration. BMC Med Genet. (2017) 18:60.

[28] Zhong Z, Zhang Q, Tao H, Sang W, Cui L, Qiang W, et al. Anti-inflammatory activities of Sigesbeckiaglabrescens Makino: combined in vitro and in silico investigations. Chin Med. (2019) 14:35.

[29] Kharat, Mahesh, et al. "Physical and Chemical Stability of Curcumin in Aqueous Solutions and Emulsions: Impact of pH, Temperature, and Molecular Environment." Journal of agricultural and food chemistry 65(8) (2017) 1525-1532.

[30] Okimoto RA, Lin L, Olivas V, et al. Preclinical efficacy of an RAF inhibitor that evades paradoxical MAPK pathway activation in protein kinase BRAF-mutant lung cancer. ProcNatlAcadSci U S A (2016) 113:13456-61.

[31] Amaral T, Sinnberg T, Meier F, et al. MAPK pathway in melanoma part II-secondary and adaptive resistance mechanisms to BRAF inhibition. Eur J Cancer (2017) 73:93-101

[32] Rudin CM, Hong K, Streit M. Molecular characterization of acquired resistance to the BRAF inhibitor dabrafenib in a patient with BRAF-mutant non-small-cell lung cancer. J ThoracOncol (2013) 8:e41-2.

[33] Spagnolo F, Ghiorzo P, Queirolo P. Overcoming resistance to BRAF inhibition in BRAF-mutated metastatic melanoma. Oncotarget (2014) 5:10206-21.

[34] Jain P, Silva A, Han HJ, et al. Overcoming resistance to single-agent therapy for oncogenic BRAF gene fusions via combinatorial targeting of MAPK and PI3K/mTORsignaling pathways. Oncotarget (2017) 8:84697-713.

[35] Marchetti A, Felicioni L, Malatesta S, et al. Clinical features and outcome of patients with non-small-cell lung cancer harboring BRAF mutations. J ClinOncol (2011) 29:3574-9.

[36] Paik PK, Arcila ME, Fara M, et al. Clinical characteristics of patients with lung adenocarcinomas harboring BRAF mutations. J ClinOncol (2011) 29:2046-51.

[37] Cardarella S, Ogino A, Nishino M, et al. Clinical, pathologic, and biologic features associated with BRAF mutations in non-small cell lung cancer. Clin Cancer Res (2013) 19:4532-40.

[38] Ding X, Zhang Z, Jiang T, et al. Clinicopathologic characteristics and outcomes of Chinese patients with non-small-cell lung cancer and BRAF mutation. Cancer Med (2017) 6:555-62.

[39] Sasaki H, Endo K, Okuda K, Kawano O, Kitahara N, Tanaka H, et al. Epidermal growth factor receptor gene amplification and gefitinib sensitivity in patients with recurrent lung cancer. J Cancer Res ClinOncol. (2008)134:469–77.

[40] Gupta R, Dastane AM, Forozan F, Riley-Portuguez A, Chung F, Lopategui J, et al. Evaluation of EGFR abnormalities in patients with pulmonary adenocarcinoma: the need to test neoplasms with more than one method. Mod Pathol. (2009) 22:128–33.

[41] Ladanyi M, Pao W. Lung adenocarcinoma: guiding EGFR-targeted therapy and beyond. Mod Pathol. , (2008) 21:S16–22.

[42] Massarelli E, Varella-Garcia M, Tang X, Xavier AC, Ozburn NC, Liu DD, et al. KRAS mutation is an important predictor of resistance to therapy with epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Clin Cancer Res. (2007) 13:2890–6.

[43] Lynch TJ, Bell DW, Sordella R, Gurubhagavatula S, Okimoto RA, Brannigan BW, et al. Activating mutation in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. (2004) 350:2129–39.

[44] Balak MN, Gong Y, Riely GJ, Somwar R, Li AR, Zakowski MF, et al. Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res. (2006) 12:6494–501.

[45] Malhotra A., Nair P., Dhawan D.K. Premature mitochondrial senescence and related ultrastructural changes during lung carcinogenesis modulation by curcumin and resveratrol. Ultrastruct. Pathol. , (2012) 36:179–184.

[46] Busquets S., Ametller E., Fuster G., Olivan M., Raab V., Argiles J.M., Lopez-Soriano F.J. Resveratrol, a natural diphenol, reduces metastatic growth in an experimental cancer model. Cancer Lett., (2007)245:144–148.

[47] Tamilselvam Rajavel, KasiPandimaDevi. Phytochemicals as Epigenetic Modifiers for Cancer Management with Special Reference to Lung Cancer., (2019).

[48] S. Biswas, I. Rahman, in Bioactive Food as Dietary Interventions for Liver and Gastrointestinal Disease, (2013).

[49] FZhang S. Computer-aided drug discovery and development. In Drug Design and Discovery. , 716 (2011) 23-38.

[50] Kapetanovic IM. Computer-aided drug discovery and development (CADD): in silicon-chemical-biological approach. Chemical-biological interactions. , 171(2) (2008) 165-76.

[51] Imam SS, Gilani SJ. Computer-Aided Drug Design: A Novel Loom To Drug Discovery. Org. Med. Chem., 1(4) (2017) 1-6.

[52] Anderson AC. The process of structure-based drug design. Chemistry & biology., 10(9) (2003) 787-97.

[53] PrashantMathur, DNB, PhD[1]; Krishnan Sathishkumar, MSc[1]; MeeshaChaturvedi, MBBS[1]; Priyanka Das, B-Level[1]; KondalliLakshminarayanaSudarshan, MSc[1]; Stephen Santhappan, MSc, MPhil[1]; VinodhNallasamy, MSc, MPhil[1]; Anish John, BE[1]; Sandeep Narasimhan, MSc[1]; and Francis SelvarajRoselind, MSc[1]; JCO GLOBAL Oncology no. 6(2020) 1063-1075.

[54] SampledPharmacophore Approach, Current Computer-Aided Drug Design (2011) 7: Chayan Acharya, Andrew Coop, James E. Polli, and Alexander D. MacKerell, Recent Advances in Ligand-Based Drug Design: Relevance and Utility of the Conformationally

[55] Steinmann J., Buer J., Pietschmann T., Steinmann E. Anti-infective properties of epigallocatechin-3-gallate (EGCG), a component of green tea. Br. J. Pharmacol. (2013) 168:1059–1073. doi: 10.1111/bph.12009.

[56] Chantre P., Lairon D. Recent finding of green tea extract AR25 (Exolise) and its activity for the treatment of obesity. Phytomedicine. (2002) 9:3–8. doi: 10.1078/0944-7113-00078.

[57] Leung L.K., Su Y., Chen R. Theaflavins in black tea and catechins in green tea are equally effective antioxidants. J. Nutr., (2001) 131:2248–2251. doi: 10.1093/jn/131.9.2248.

[58] Zhang C., Suen C.L.C., Yang C., Quek S.Y. Antioxidant capacity and major polyphenol composition of teas as affected by geographical location, plantation elevation, and leaf grade. Food Chem., (2018) 244:109–119. doi: 10.1016/j.foodchem.2017.09.126.

[59] Yanagimoto K., Ochi H., Lee K.G., Shibamoto T. Antioxidative activities of volatile extracts from green tea, oolong tea, and black tea. J. Agric. Food Chem., (2003) 51:7396–7401. doi: 10.1021/jf030127i.

[60] Juneja L.R., Chu D.-C., Okubo T. L-theanine—A unique amino acid of green tea and its relaxation effect in humans. Trends Food Sci. Technol. 1999; 10:199–204. doi: 10.1016/S0924-2244(99)00044-8.

[61] Yoshizawa S., Horiuchi T., Sugimura M. Penta-o-galloyl-β-D-glucose and epigallocatechin gallate: Cancer prevention agent. Phenolic Compounds in Food and Health II. Antioxidant and cancer prevention. Washington DC. Am. Chem. Soc. 1992;2:118–119.

[62] Mazieres J, Cropet C, Montané L, Barlesi F, Souquet PJ, Quantin X, Dubos-Arvis C, Otto J, Favier L, Avrillon V, Cadranel J, Moro-Sibilot D, Monnet I, Westeel V, Le Treut J, Brain E, Trédaniel J, Jaffro M, Collot S, Ferretti GR, Tiffon C, Mahier-Ait Oukhatar C, Blay JY. Vemurafenib in non-small-cell lung cancer patients with BRAFV600 and BRAFnonV600 mutations. Ann Oncol. 2020 Feb;31(2):289-294. doi: 10.1016/j.annonc.2019.10.022. Epub 2020 Jan 3. PMID: 31959346.

[63] Hyman DM, Puzanov I, Subbiah V, Faris JE, Chau I, Blay JY, Wolf J, Raje NS, Diamond EL, Hollebecque A, Gervais R, Elez-Fernandez ME, Italiano A, Hofheinz RD, Hidalgo M, Chan E, Schuler M, Lasserre SF, Makrutzki M, Sirzen F, Veronese ML, Tabernero J, Baselga J. Vemurafenib in Multiple Nonmelanoma Cancers with BRAF V600 Mutations. N Engl J Med. 2015 Aug 20;373(8):726-36. doi: 10.1056/NEJMoa1502309. Erratum in: N Engl J Med. 2018 Oct 18;379(16):1585. PMID: 26287849; PMCID: PMC4971773.

[64] Joshi M, Rice SJ, Liu X, Miller B, Belani CP. Trametinib with or without vemurafenib in BRAF mutated non-small cell lung cancer. PLoS One. 2015 Feb 23;10(2) e0118210. doi: 10.1371/journal.pone.0118210. PMID: 25706985; PMCID: PMC4338247.

[65] Robinson SD, O'Shaughnessy JA, Cowey CL, Konduri K. BRAF V600E-mutated lung adenocarcinoma with metastases to the brain responding to treatment with vemurafenib. Lung Cancer., 85(2) (2014) 326-30. doi: 10.1016/j.lungcan.2014.05.009. Epub 2014 May 21. PMID: 24888229.

[66] Zubair H, Azim S, Ahmad A, et al. Cancer Chemoprevention by Phytochemicals: Nature's Healing Touch. Molecules., 22(3) (2017) 395. Published 2017 Mar 3. doi:10.3390/molecules22030395;20(20):4981.

[67] Ranjan A, Ramachandran S, Gupta N, et al. Role of Phytochemicals in Cancer Prevention. Int J Mol Sci., (2019).

[68] Efferth, Thomas, et al., Integration of phytochemicals and phytotherapy into cancer precision medicine., Oncotarget ., 8(30) (2017) 50284-50304. doi:10.18632/oncotarget.17466.

[69] Jones V, Katiyar SK. Emerging phytochemicals for prevention of melanoma invasion. Cancer Lett., 335(2) (2013) 251-258. doi:10.1016/j.canlet.2013.02.056.

[70] Zhang L, Huang Y, Zhuo W, Zhu Y, Zhu B, Chen Z. Fisetin, a dietary phytochemical, overcomes Erlotinib-resistance of lung adenocarcinoma cells through inhibition of MAPK and AKT pathways. Am J Transl Res., 8(11) (2016) 4857-4868. Published 2016o

[71] Chirumbolo S, Bjørklund G, Lysiuk R, Vella A, Lenchyk L, Upyr T. Targeting Cancer with Phytochemicals via Their Fine-Tuning of the Cell Survival Signaling Pathways. Int J Mol Sci., 19(11) (2018) 3568. Published 2Singh S, Sharma B, Kanwar SS, Kumar A. Lead Phytochemicals for Anticancer Drug Development. Front Plant Sci. 2016; 7:1667. Published 2016 Nov 8. doi:10.3389/fpls.2016.01667018 Nov 12

[72] Hosseini A, Ghorbani A. Cancer therapy with phytochemicals: evidence from clinical studies. Avicenna J Phytomed. , 5(2) (2015) 84-97.

[73] Wang H, Khor TO, Shu L et al. Plants vs. cancer: a review on natural phytochemicals in preventing and treating cancers and their druggability. Anticancer Agents Med Chem. 12(10) (2012) 1281-1305. Doi: 10.2174/187152012803833026.

[74] Dr.P.Gopiraman, "Cigarette Smoking Induced Human Cellular Oxidative Deregulations" SSRG International Journal of Applied Chemistry 2.1 (2015): 1-4.